Bleeders, bleeding rates, and bleeding score

Area of Science:

• Hematology
• Clinical Medicine
• Medical Diagnostics

Background:

• Differentiating healthy individuals from those with mild bleeding disorders (MBDs) is clinically challenging due to overlapping bleeding symptoms.
• Existing frameworks struggle to unify bleeding risk across diverse congenital and acquired coagulopathies.

Purpose of the Study:

• To introduce and validate the concept of 'bleeding rate' as a unifying metric for bleeding risk.
• To demonstrate how bleeding rate can reconcile bleeding observations in various hemorrhagic conditions.

Main Methods:

• Analysis of incidence data from primary prevention trials and observational studies on hemorrhagic disorders.
• Comparison of non-major bleeding rates in healthy subjects, MBD patients (e.g., type 1 VWD), and patients on antiplatelet drugs.
• Comparison of bleeding rates in moderately severe bleeding disorders (e.g., type 2 VWD) with patients on vitamin K antagonists.

Main Results:

• The incidence of non-major bleeding in healthy subjects is approximately five per 100 person-years.
• Non-major bleeding rates in MBD patients (e.g., type 1 VWD) are comparable to those on antiplatelet therapy.
• Bleeding rates in more severe disorders (e.g., type 2 VWD) parallel those in patients taking vitamin K antagonists.

Conclusions:

• The bleeding rate model offers a unified framework to understand and quantify bleeding risk across different coagulopathies.
• This model explains common clinical observations and has the potential to guide the development of improved diagnostic and predictive tools for bleeding disorders.